| |
|
|
 |
|
send
print
|
|
|
|
|
Visp, Switzerland
|
|
|
Lonza's FDA-inspected production site in Visp is staffed by approximately 2,600 people and comprises, in addition to the custom manufacturing facilities, activities in the area of organic fine chemicals, peptides, oligonucleotides, and microbial biopharmaceuticals.
Lonza's cGMP commercial-scale fine chemical complex (FCC) comprises 6 state-of-the-art, multi-purpose facilities, supported by multi-purpose plants for starting materials.
● total reactor volume: 407m3
● typical reactor volume: 10m3
● cGMP phosgene 10m3 plant integrated
● several low-temperature modules
● several solvent recovery plants
We also offer a wide range of ISO-regulated capabilities out of Visp, Swizerland.
● highly flexible production concept
● reactor volumes from 250L up to 16m3
● ideal for quantities > 10 mt to 1,000 mt
● low (–90°C) to high (650°C) temperature reactions
● high-pressure reactions (80 atm)
● back-integrated (diketene, ketene, HCN, acetylene)
Small-scale capabilities in Visp, Switzerland
Launch-scale capabilities in Visp, Switzerland
|
Riverside, PA - USA
|
|
|
Lonza’s FDA inspected, cGMP custom manufacturing facility is supported by 160 people and is approved for manufacture of DEA controlled substances.
● total reactor volume: 134m3
● reactor sizes: 1 to 4m3
● launch quantities (30kg) to commercial scale (over 200 mt)
● hastelloy production train
● on-site process development services and analytical support
|
Nansha, China
|
|
|
Lonza’s new API plant in Nansha, China, combines state-of-the-art facilities and development services with advanced pharmachemical manufacturing processes.
● typical reactor volume: 10m3
● additional large-scale capacity planned
● on-site process development services and analytical support
Small-scale capabilities in Nansha, China
|
|
|
|
|
|
|
|
|
 |
